U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 7

1.
MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer
Joshua P. Plotnik, Zheng Zha, Weiguo Feng, Irene Lee, Jacob Riehm, Ryan A. McClure, Stephanie Sandoval, Tamar Uziel, Erin Murphy, Xin Lu, Lloyd T. Lam
Mol Cancer Res. 2024 Aug 2; 22(8): 689–698. Published online 2024 May 15. doi: 10.1158/1541-7786.MCR-23-0599
PMCID:
PMC11294817
AbstractArticlePDF–3.4M
2.
IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression
Sven Hagemann, Danny Misiak, Jessica L. Bell, Tommy Fuchs, Marcell I. Lederer, Nadine Bley, Monika Hämmerle, Ehab Ghazy, Wolfgang Sippl, Johannes H. Schulte, Stefan Hüttelmaier
Mol Cancer. 2023; 22: 88. Published online 2023 May 29. doi: 10.1186/s12943-023-01792-0
PMCID:
PMC10226260
AbstractArticlePDF–6.5M
3.
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML
DANIEL H. ALBERT, NEAL C. GOODWIN, ANGELA M. DAVIES, JENNY ROWE, GEROLD FEUER, MICHAEL BOYIADZIS, KATHLEEN A. DORRITIE, MARIA MANCINI, REGINA GANDOUR-EDWARDS, BRIAN A. JONAS, GAUTAM BORTHAKUR, IBRAHIM ALDOSS, DAVID A. RIZZIERI, OLATOYOSI ODENIKE, THOMAS PREBET, SANJANA SINGH, RELJA POPOVIC, YU SHEN, KEITH F. MCDANIEL, WARREN M. KATI, DIMPLE A. MODI, MONICA MOTWANI, JOHANNES E. WOLFF, DAVID J. FROST
In Vivo. 2022 Jul-Aug; 36(4): 1615–1627. Published online 2022 Jul 3. doi: 10.21873/invivo.12872
PMCID:
PMC9301399
AbstractArticlePDF–5.6M
4.
Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells
Mina Baek, Jin Choul Chai, Hae In Choi, Eunyoung Yoo, Bert Binas, Young Seek Lee, Kyoung Hwa Jung, Young Gyu Chai
PLoS One. 2022; 17(4): e0266966. Published online 2022 Apr 29. doi: 10.1371/journal.pone.0266966
PMCID:
PMC9053788
AbstractArticlePDF–4.3M
5.
A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
Gautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, David A. Rizzieri, Thomas Prebet, Chris Chen, Relja Popovic, Dimple A. Modi, Rujuta H. Joshi, Johannes E. Wolff, Brian A. Jonas
Cancer. 2021 Aug 15; 127(16): 2943–2953. Published online 2021 May 2. doi: 10.1002/cncr.33590
PMCID:
PMC8360206
AbstractArticlePDF–383K
6.
Inhibition of the BET family reduces its new target gene IDO1 expression and the production of l-kynurenine
Chang-Qing Tian, Lin Chen, Hua-Dong Chen, Xia-Juan Huan, Jian-Ping Hu, Jing-Kang Shen, Bing Xiong, Ying-Qing Wang, Ze-Hong Miao
Cell Death Dis. 2019 Aug; 10(8): 557. Published online 2019 Jul 19. doi: 10.1038/s41419-019-1793-9
PMCID:
PMC6642217
AbstractArticlePDF–2.2M
7.
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
Warren Fiskus, Tianyu Cai, Courtney D. DiNardo, Steven M. Kornblau, Gautam Borthakur, Tapan M. Kadia, Naveen Pemmaraju, Prithviraj Bose, Lucia Masarova, Kimal Rajapakshe, Dimuthu Perera, Cristian Coarfa, Christopher P. Mill, Dyana T. Saenz, David N. Saenz, Baohua Sun, Joseph D. Khoury, Yu Shen, Marina Konopleva, Kapil N. Bhalla
Blood Cancer J. 2019 Feb; 9(2): 4. Published online 2019 Jan 15. doi: 10.1038/s41408-018-0165-5
PMCID:
PMC6333829
AbstractArticlePDF–2.1M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center